Connect your AI

Tango Therapeutics TNGX Total Equity

Total Equity at other companies

Bristol-Myers SquibbBMY

$20.07B+15.4%

AmgenAMGN

$9.19B+48.1%

Gilead SciencesGILD

$23.52B+22.7%

ExelixisEXEL

$1.94B-9.2%

Cogent Biosciences, Inc.COGT

$607.69M+177%

CG OncologyCGON

$1.09B+54.9%

Other financials

Income statement

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total assets$435.8M+58.9%

Cash flow

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

Market cap$4.55B+1,915%

Enterprise value$4.43B+2,204%

P/S79.9×+74.4×

Profitability

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Tango Therapeutics's total equity?: Tango Therapeutics (TNGX) reported total equity of $391.51M in Q1 2026.
How has Tango Therapeutics's total equity changed year-over-year?: Tango Therapeutics's total equity increased by 134.8% year-over-year, from $166.76M to $391.51M.
What is the long-term trend for Tango Therapeutics's total equity?: Over 5 years (2020 to 2025), Tango Therapeutics's total equity has grown at a 55.1% compound annual growth rate (CAGR), from $38.6M to $346.18M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.